Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT05429632
Trial Phases:	Phase III	Protocol IDs:	Priothera SAS (primary) NCI-2022-10700
Eligibility:	18 - 75 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Priothera SAS
NCI Full Details:	http://clinicaltrials.gov/show/NCT05429632

Summary

This is a multi-center, randomized, double-blinded, placebo controlled trial.

Objectives

The purpose of this study is to evaluate the efficacy and safety of mocravimod as an
adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients
undergoing allogeneic hematopoietic cell transplantation (HCT).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.